학술논문
697P - A phase I, open-label, multi-center, dose-escalation study of codrituzumab, an anti-glypican-3 monoclonal antibody, in combination with atezolizumab in patients with locally advanced or metastatic hepatocellular carcinoma
Document Type
Abstract
Author
Source
In Annals of Oncology October 2018 29 Supplement 8
Subject
Language
ISSN
0923-7534